Title |
Interventions for preventing and treating kidney disease in Henoch-Schönlein Purpura (HSP)
|
---|---|
Published in |
Cochrane database of systematic reviews, July 2009
|
DOI | 10.1002/14651858.cd005128.pub2 |
Pubmed ID | |
Authors |
Chartapisak, Wattana, Opastirakul, Sauwalak, Hodson, Elisabeth M, Willis, Narelle S, Craig, Jonathan C |
Abstract |
To determine the benefits and harms of therapies used to prevent or treat kidney disease in Henoch-Schönlein Purpura (HSP). To evaluate the benefits and harms of different agents (used singularly or in combination) compared with placebo or no treatment or another agent for the prevention or treatment of kidney disease in patients with HSP. Randomised controlled trials (RCTs) and quasi-RCTs were identified from the Cochrane Renal Group's specialised register, the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE and EMBASE using optimally sensitive search strategies combined with search terms for HSP. RCTs comparing any intervention used to prevent or treat kidney disease in HSP compared with placebo, no treatment or other agents were included. Three authors independently assessed trial quality and extracted data from each study. Statistical analyses were performed using the random effects model and the results were expressed as risk ratio (RR) for dichotomous outcomes and mean difference (MD) for continuous outcomes with 95% confidence intervals (CI). Ten studies (1230 children) were identified. There was no significant difference in the risk of persistent kidney disease at six months (3 studies, 379 children: RR 0.51, 95% CI 0.24 to 1.11) and 12 months (3 studies, 498 children: RR 1.02, 95% CI 0.40 to 2.62) in children given prednisone for 14 to 28 days at presentation of HSP compared with placebo or supportive treatment. In children with severe kidney disease, there was no significant difference in the risk of persistent kidney disease with cyclophosphamide compared with supportive treatment (1 study, 56 children: RR 1.07, 95% CI 0.65 to 1.78) and with cyclosporin compared with methylprednisolone (1 study, 19 children: RR 0.39, 95% CI 0.14 to 1.06). Data from RCTs for any intervention used in improve kidney outcomes in children with HSP are very sparse except for short-term prednisone. There was no evidence of benefit of prednisone in preventing serious long-term kidney disease in HSP. |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
United Kingdom | 1 | 2% |
South Africa | 1 | 2% |
Unknown | 52 | 96% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Master | 10 | 19% |
Student > Postgraduate | 7 | 13% |
Student > Ph. D. Student | 6 | 11% |
Student > Doctoral Student | 6 | 11% |
Student > Bachelor | 5 | 9% |
Other | 13 | 24% |
Unknown | 7 | 13% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 39 | 72% |
Nursing and Health Professions | 3 | 6% |
Social Sciences | 2 | 4% |
Agricultural and Biological Sciences | 1 | 2% |
Arts and Humanities | 1 | 2% |
Other | 2 | 4% |
Unknown | 6 | 11% |